$2bn deal sees uniQure license haemophilia B gene therapy to CSL BehringUniQure has signed a deal that could be worth over $2 billion with CSL Behring – giving the Share X$2bn deal sees uniQure license haemophilia B gene therapy to CSL Behringhttps://pharmaphorum.com/news/2bn-deal-sees-uniqure-license-haemophilia-b-gene-therapy-to-csl-behring/
CSL, BrightInsight team up on digital health for rare diseasesCSL Behring has signed a deal with US firm BrightInsight to develop digital health products to help patients Share XCSL, BrightInsight team up on digital health for rare diseaseshttps://pharmaphorum.com/news/csl-brightinsight-team-up-on-digital-health-for-rare-diseases/
Plasma firms join forces on “unbranded” coronavirus treatmentA group of companies that specialise in plasma-derived drugs will pool their resources to try to develop a Share XPlasma firms join forces on “unbranded” coronavirus treatmenthttps://pharmaphorum.com/news/plasma-firms-join-forces-on-unbranded-coronavirus-treatment/
CSL accuses ex-exec, now at Pharming, of stealing trade secretsCSL Behring has filed a lawsuit against a former employee, claiming he stole sensitive information with the intention Share XCSL accuses ex-exec, now at Pharming, of stealing trade secretshttps://pharmaphorum.com/news/csl-accuses-ex-exec-now-at-pharming-of-stealing-trade-secrets/
Taking plasma from donor to patientLutz Bonacker from CSL Behring tells us about the unique aspects of working with plasma-derived medicines and how Share XTaking plasma from donor to patienthttps://pharmaphorum.com/views-and-analysis/taking-plasma-from-donor-to-patient/
CSL Behring lung drug would cost NHS £8m per patient, says NICENICE has rejected CSL Behring’s alpha1-proteinase inhibitor Respreeza for treating genetic emphysema in draft guidance, saying that it Share XCSL Behring lung drug would cost NHS £8m per patient, says NICEhttps://pharmaphorum.com/news/csl-behring-lung-drug-would-cost-nhs-8m-per-patient-says-nice/
Could digital technology revolutionise pharma in 2018?This year’s eyeforpharma conference in Barcelona outlined how 2018 could be a turning point for the industry. As Share XCould digital technology revolutionise pharma in 2018?https://pharmaphorum.com/views-and-analysis/digital-technology-revolutionise-pharma-2018/
